The microbiome and human cancer
Open accessThe DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index; 65 of the 179 sources its claims cite were checked for support.
Abstract
BACKGROUND: Historical accounts linking cancer and microbes date as early as four millennia ago. After establishment of the germ theory of infectious diseases, clinical research of microbial influences on cancer began in 1868, when William Busch reported spontaneous tumor regressions in patients with Streptococcus pyogenes infections. Over the next century, poor reproducibility, erroneous microbiological claims, and severe toxicity led many to discount the role of bacteria in carcinogenesis and cancer therapy. However, these studies provided the first crude demonstrations of cancer immunotherapy. Contemporaneously, the viral theory of cancer flourished, spurred by the 1911 discovery of Rous sarcoma virus, which transformed benign tissue into malignant tumors in chickens. The decades-long search to find viruses behind every human cancer ultimately failed, and many cancers have been linked to somatic mutations. Now the field is encountering intriguing claims of the importance of microbes, including bacteria and fungi, in cancer and cancer therapy. This Review critically evaluates this evidence in light of modern cancer biology and immunology, delineating roles for microbes in cancer by examining advances in proposed mechanisms, diagnostics, and modulation strategies. ADVANCES: Few microbes directly cause cancer, but many seem complicit in its growth, often acting through the host’s immune system; conversely, several have immunostimulatory properties. Mechanistic analyses of gut microbiota–immune system interactions reveal powerful effects on antitumor immunity by modulating primary and secondary lymphoid tissue activities. Many of these pathways invoke Toll-like receptor–initiated cytokine signaling, but microbial metabolic effects and antigenic mimicry with cancer cells are also important. In preclinical models, microbial metabolites also regulate phenotypes of tumor somatic mutations and modulate immune checkpoint inhibitor efficacy. Emerging evidence suggests that intratumoral bacteria exist and are active, with overlapping immunohistochemistry, immunofluorescence, electron microscopy, and sequencing data in ~10 cancer types. Preliminary studies further suggest that fungi and bacteriophages contribute to gastrointestinal cancers. However, the abundance of intratumoral microbial cells is low relative to cancer cells, and knowledge of their functional repertoire and potency remains limited. Further validation of their prevalence and impact is needed in diverse cohorts and therapeutic contexts. The immunomodulatory effects of host microbiota have reinvigorated efforts to change their composition as a form of immunotherapy. Despite extensive preclinical evidence, translation of microbiota modulation approaches into humans has not yet materialized into commercialized therapies. Synthetic biology approaches are also gaining traction, with engineered bacterial cancer therapies in preclinical and clinical trial settings. OUTLOOK: A better understanding of the roles of microbes in cancer provides an opportunity to improve each stage of the cancer care cycle, but major challenges remain. Concerted efforts to characterize cancer-associated microbiota among tumor, stool, and blood samples with gold-standard contamination controls would tremendously aid this progress. This would be analogous to The Cancer Genome Atlas’s role in characterizing the cancer somatic mutation landscape. Large-scale clinical trials are currently testing the efficacy of microbiota modulation approaches, ranging from dietary modifications to intratumorally injected, engineered bacteria. These bacterial cancer therapies, if safe and effective, could tremendously expand the cancer therapy armamentarium. Altogether, integrating the host-centric and microbial viewpoints of cancer may improve patient outcomes while providing a nuanced understanding of cancer-host-microbial evolution. Opportunities for microbes to affect cancer care.: Diagnosis: Cancer-specific, blood-borne microbial DNA may complement cell-free tumor DNA (ctDNA). Prognosis: Gut and intratumoral microbiota may stratify patient outcomes (NR, nonresponder; R, responder; TME, tumor microenvironment). Therapy: Intratumor injection of CD47 nanobody (CD47nb)–producing Escherichia coli may create systemic antitumor immunity by enhancing dendritic cell (DC) phagocytosis, lymph node (LN) antigen (Ag) presentation, and cytotoxic T lymphocyte (CTL) activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
28 Valid · 4 Not valid · 64 Not checked · 22 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“the number of microbes that inhabit the human body (roughly equal to the number of human cells)”
§ The microbiome and human cancer > Abstract > OUTLOOK:
What the sources say
- Supportedcites [27] Sender R, Fuchs S, Milo R, Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 14, e1002533 (2016). 27541692 PMC4991899 source
The Results section 'The Ratio of Bacteria to Human Cells in the Adult Body' states B/H = 1.3 (3.8·10^13 bacteria vs 3.0·10^13 human cells in the 70 kg reference man), explicitly described as 'about 1:1' replacing the 10:1 or 100:1 values. The Abstract likewise says the number of bacteria is 'of the same order as the number of human cells', and Table 3 shows the ratio stays near parity (1.3–2.3) across women, infants, elderly and obese segments. The paper also operationally equates 'microbial cells' with bacteria, since bacteria dominate the microbiome by 2–3 orders of magnitude. (LLM, conf=0.92)
- Disputedcites [28] Belkaid Y, Naik S, Compartmentalized and systemic control of tissue immunity by commensals. Nat. Immunol 14, 646– 653 (2013). 23778791 PMC3845005 sourceExperimental — accuracy not yet measured
Our copy states the opposite ratio: in 'Distinct anatomical sites have unique commensal communities' it says that with an estimated 100 trillion cells, commensals outnumber host cells by at least a factor of ten (and encode at least 100-fold more unique genes). No passage anywhere in the paper describes microbial and human cell numbers as roughly equal; searches for 'outnumber host cells / 100 trillion' and for 'number of microbial cells relative to human cells equal' returned only that sentence and unrelated topical passages. The parenthetical the citing sentence attributes to this source therefore contradicts what the source asserts. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [29] Fung TC, Olson CA, Hsiao EY, Interactions between the microbiota, immune and nervous systems in health and disease. Nat. Neurosci 20, 145– 155 (2017). 28092661 PMC6960010 sourceExperimental — accuracy not yet measured
The Abstract of Fung, Olson & Hsiao (2017) states that 'The human gastrointestinal tract is colonized by trillions of microorganisms collectively termed the gut microbiota', which supports the framing that the human body harbours an enormous microbial population, but locates it in the GI tract rather than the whole body. No passage in our copy compares microbial numbers to the number of human cells or states anything like a ~1:1 (or 10:1) ratio; searches for 'microbial cells outnumber human cells ratio tenfold', 'number of human cells', and microbiota diversity/abundance returned only the trillions-of-microorganisms statement and unrelated neuroimmune content. The quantitative equivalence attributed to this source is therefore not in our copy. (LLM, conf=0.72)
- Partly supportedcites [30] Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF, The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 359, 1366– 1370 (2018). 29567708 sourceExperimental — accuracy not yet measured
The only quantitative statement in our copy is in 'Early steps: A role for the microbiome in cancer': 'The human gut microbiome contains ~3 × 10^13 bacteria, most of which are commensals (5)' — a gut-restricted bacterial count, credited to reference 5. Nothing in our copy states a number of human cells or compares microbial counts to human cell counts, so the claim's central equivalence ('roughly equal to the number of human cells') and the whole-body scope are not supported by this source. Searches for 'number of human cells', 'microbial cells outnumber human cells', and '10^14' returned no such comparison; the paper does describe the host as a 'meta-organism' shaped by the gut microbiome, without any ratio to host cells. (LLM, conf=0.65)
- Not checked yetcites [31] Garrett WS, Cancer and the microbiota. Science. 348, 80– 86 (2015). 25838377 PMC5535753 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increasing evidence suggests an important additional category of “complicit” microbes and microbial functions that promote carcinogenesis but are insufficient to cause cancer (18, 20, 25, 38, 44–47).”
§ The microbiome and human cancer > Overview of the cancer microbiome
What the sources say
- Supportedcites [18] Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, Ameh S, Sandel D, Liang XS, Mazzilli S, Whary MT, Meyerson M, Germain R, Blainey PC, Fox JG, Jacks T, Commensal Microbiota Promote Lung Cancer Development via γδ T Cells. Cell. 176, 998– 1013.e16 (2019). 30712876 PMC6691977 source
The Results (page unavailable) show that commensal microbiota increased tumor growth in mice whose lung tumors were initiated by Kras activation and p53 deletion. The Discussion (page unavailable) likewise describes early tumor development arising from those genetic changes, with local microbiota amplifying the response that promotes progression. This supports the cited paper as an example of microbes that promote carcinogenesis without being sufficient to initiate it. (LLM, conf=0.88)
- Partly supportedcites [20] Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, Shadaloey SA, Wu D, Preiss P, Verma N, Guo Y, Saxena A, Vardhan M, Diskin B, Wang W, Leinwand J, Kurz E, Kochen Rossi JA, Hundeyin M, Zambrinis C, Li X, Saxena D, Miller G, The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 574, 264– 267 (2019). 31578522 PMC6858566 sourceExperimental — accuracy not yet measured
The paper reports that fungal ablation protected against pancreatic tumor progression and that repopulation with Malassezia accelerated it (Abstract; page unavailable). Its experiments used mice with oncogenic Kras or implanted tumor cells, and it does not establish that the fungi are insufficient to cause cancer on their own. It also says whether fungal changes are a cause or consequence of oncogenesis is difficult to answer fully. (LLM, conf=0.86)
- Partly supportedcites [25] Tsay J-CJ, Wu BG, Sulaiman I, Gershner K, Schluger R, Li Y, Yie T-A, Meyn P, Olsen E, Perez L, Franca B, Carpenito J, Iizumi T, El-Ashmawy M, Badri M, Morton JT, Shen N, He L, Michaud G, Rafeq S, Bessich JL, Smith RL, Sauthoff H, Felner K, Pillai R, Zavitsanou A-M, Koralov SB, Mezzano V, Loomis CA, Moreira AL, Moore W, Tsirigos A, Heguy A, Rom WN, Sterman DH, Pass HI, Clemente JC, Li H, Bonneau R, Wong K-K, Papagiannakopoulos T, Segal LN, Lower airway dysbiosis affects lung cancer progression. Cancer Discov. (2020), doi: 10.1158/2159-8290.CD-20-0263. PMC7858243 33177060 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable in our copy) says that oral commensals such as Veillonella contribute to a pro-tumor immune environment and progression of existing non-small-cell lung cancer. The Methods describe introducing Veillonella after lung cancer was established in mice. This supports a role in progression, but the paper does not establish that these microbes or their functions are insufficient to cause cancer on their own. (LLM, conf=0.82)
- Supportedcites [38] Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F, Sears CL, Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 359, 592– 597 (2018). 29420293 PMC5881113 source
The paper reports that, in carcinogen-treated mice, either bacterial strain alone produced few to no tumors, whereas co-colonization produced pronounced tumor induction. It proposes complementary microbial mechanisms that enhance carcinogenesis, supporting the citing sentence’s point that microbes can contribute to cancer without being sufficient on their own. The supplied copy gives no page numbers. (LLM, conf=0.85)
- Supportedcites [44] Kadosh E, Snir-Alkalay I, Venkatachalam A, May S, Lasry A, Elyada E, Zinger A, Shaham M, Vaalani G, Mernberger M, Stiewe T, Pikarsky E, Oren M, Ben-Neriah Y, The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature. 586, 133– 138 (2020). 32728212 PMC7116712 source
The Discussion (page unavailable) reports that the native gut microbiota or gallic acid converts mutant p53’s tumour-suppressive effect into oncogenic activity. In “Gallic acid mimics the microbiota effect” (page unavailable), gallic acid promotes dysplasia in mice with CKIα ablation and mutant p53, but has no effect on tumorigenesis in the tested mice with wild-type p53. This supports the cited paper as an example of a microbial function that promotes carcinogenesis in a susceptible context rather than causing it on its own. (LLM, conf=0.87)
- Partly supportedcites [45] Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF, Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 360 (2018), doi: 10.1126/science.aan5931. PMC6407885 29798856 sourceExperimental — accuracy not yet measured
The Results and ‘Alterations in the gut microbiome suppress liver tumors in multiple mouse models’ sections report that changing gut bacteria or bile-acid metabolism changes liver tumor growth, supporting a role for microbial functions in promoting cancer. The experiments used MYC-induced tumors or implanted tumor cells; they do not establish the broader claim that these microbes or functions are insufficient to cause cancer on their own. No page numbers are provided in our copy. (LLM, conf=0.84)
- Partly supportedcites [46] Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A, Tagliabue E, Sfondrini L, Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. Cell Rep. 24, 3528– 3538 (2018). 30257213 sourceExperimental — accuracy not yet measured
The Discussion says lung commensal microbes can provide immunosuppressive signals, and the results show that changing the lung microbiota reduced metastasis implantation in mice given tumor cells. This supports a microbial role in facilitating cancer spread, but the paper does not establish a general category of “complicit” microbes that promote carcinogenesis, or explicitly assess whether those microbes can cause cancer on their own. The indexed passages provide section labels but no page numbers. (LLM, conf=0.83)
- Partly supportedcites [47] Meisel M, Hinterleitner R, Pacis A, Chen L, Earley ZM, Mayassi T, Pierre JF, Ernest JD, Galipeau HJ, Thuille N, Bouziat R, Buscarlet M, Ringus DL, Wang Y, Li Y, Dinh V, Kim SM, McDonald BD, Zurenski MA, Musch MW, Furtado GC, Lira SA, Baier G, Chang EB, Eren AM, Weber CR, Busque L, Godley LA, Verdú EF, Barreiro LB, Jabri B, Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 557, 580– 584 (2018). 29769727 PMC6238954 sourceExperimental — accuracy not yet measured
The Abstract reports that microbial signals drive pre-leukaemic myeloproliferation in Tet2-deficient mice, supporting a role for microbes in a precancerous condition that also requires host susceptibility. But the Abstract and Extended Data explicitly say whether those signals promote the additional mutations leading to leukaemia remains undetermined; the paper does not establish that they promote cancer itself. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Experimental evidence also implicates several microbes with virulence factors that amplify tumorigenesis via E-cadherin/Wnt/β-Catenin signaling, including FadA from Fusobacterium nucleatum and AvrA from several Salmonella strains (42, 43).”
§ The microbiome and human cancer > Overview of the cancer microbiome
What the sources say
- Partly supportedcites [42] Silva-García O, Valdez-Alarcón JJ, Baizabal-Aguirre VM, Wnt/β-Catenin Signaling as a Molecular Target by Pathogenic Bacteria. Front. Immunol 10, 2135 (2019). 31611869 PMC6776594 sourceExperimental — accuracy not yet measured
Our copy supports the AvrA/Salmonella half: the 'Salmonella enterica sv Typhimurium' section states that AvrA enhances β-catenin deubiquitination/stability and induces Wnt2, Wnt3, Wnt6, Wnt9a and Wnt11 (also tabulated in Table 1, Introduction), and concludes these effects 'may contribute to chronic disease and cell proliferation, leading to tumor development and cancer.' However, Fusobacterium nucleatum and FadA appear nowhere in our copy (searched: Fusobacterium, FadA, nucleatum); Table 1's inventory of bacteria with Wnt/β-catenin-affecting virulence factors does not include them, so that half of the claim is not attributable to this source. Additionally, the E-cadherin arm of the mechanism is described here for B. fragilis toxin, H. parasuis and H. pylori CagA, not for AvrA, and the tumorigenic outcome for AvrA is stated as a possibility ('may promote,' 'tempting to speculate') rather than the asserted amplification of tumorigenesis the citing sentence carries. (LLM, conf=0.82)
- Supportedcites [43] Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW, Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 14, 195– 206 (2013). 23954158 PMC3770529 source
Our copy of Rubinstein et al. (2013) states exactly the FadA/F. nucleatum half of the sentence: the INTRODUCTION summary reports that 'FadA modulates E-cadherin and activates β-catenin signaling, leading to increased expression of transcription factors, oncogenes, Wnt genes... as well as growth stimulation of CRC cells', the RESULTS (FadAc activates E-cadherin-mediated cellular signaling) show β-catenin nuclear translocation and CRT/TOPFlash activation dependent on E-cadherin and β-catenin, and the xenograft RESULTS (p. Fig. 6) show FadA increased HCT116 tumor growth by 20% via E-cadherin binding — i.e., a microbial virulence factor amplifying tumorigenesis through E-cadherin/Wnt/β-catenin. The DISCUSSION also frames the paper as reporting 'a mechanism by which Fn modulates E-cadherin/β-catenin signaling'. The AvrA/Salmonella clause of the citing sentence is carried by the companion citation in the (42, 43) pair; our copy contains no mention of Salmonella or AvrA (searched: AvrA, Salmonella, other bacterial virulence factors), so it neither supports nor contradicts that half — the only other microbe it credits with an E-cadherin/β-catenin mechanism is Bacteroides fragilis enterotoxin BFT (Wu et al., 1998; 2003). (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The TME comprises not only stromal, tumor, endothelial cells, and hematopoietic progenitor-derived immune components, but also a dense network of adrenergic nerve fibres that influence oncogenesis in brain and non-brain cancers (94–97).”
§ The microbiome and human cancer > Overview of the cancer microbiome > Mechanisms and interactions between the gut and tumor microbiome
What the sources say
- Partly supportedcites [94] Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA, Cai Y, Wang R, Knutsen E, Shimizu M, Ivan C, Rao X, Wang J, Silverman DA, Tam S, Zhao M, Caulin C, Zinger A, Tasciotti E, Dougherty PM, El-Naggar A, Calin GA, Myers JN, Loss of p53 drives neuron reprogramming in head and neck cancer. Nature. 578, 449– 454 (2020). 32051587 PMC9723538 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes adrenergic neo-nerves in the oral-cancer microenvironment and says neo-neural networks provide signals that coordinate cancer progression. The cited paper does not establish a dense adrenergic network in both brain and non-brain cancers, or document the sentence’s full list of microenvironmental cell types. (LLM, conf=0.87)
- Not checked yetcites [95] Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, Körber C, Kardorff M, Ratliff M, Xie R, Horstmann H, Messer M, Paik SP, Knabbe J, Sahm F, Kurz FT, Acikgöz AA, Herrmannsdörfer F, Agarwal A, Bergles DE, Chalmers A, Miletic H, Turcan S, Mawrin C, Hänggi D, Liu H-K, Wick W, Winkler F, Kuner T, Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 573, 532– 538 (2019). 31534219 source
- Partly supportedcites [96] Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, McCabe BD, Galván JA, Robinson HPC, Zlobec I, Ciriello G, Hanahan D, Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 573, 526– 531 (2019). 31534217 PMC6837873 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) supports a narrower point: interactions with neurons promote growth of breast-cancer metastases in the brain. The Introduction (page unavailable) also reports earlier findings on NMDAR signalling in pancreatic cancers. Neither passage describes a dense network of adrenergic nerve fibres or establishes the stated list of tumour-microenvironment components; the Discussion treats comparable interactions with peripheral nerves as a question for future study. (LLM, conf=0.84)
- Partly supportedcites [97] Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, Tam LT, Espenel C, Ponnuswami A, Ni L, Woo PJ, Taylor KR, Agarwal A, Regev A, Brang D, Vogel H, Hervey-Jumper S, Bergles DE, Suvà ML, Malenka RC, Monje M, Electrical and synaptic integration of glioma into neural circuits. Nature. 573, 539– 545 (2019). 31534222 PMC7038898 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) identifies neurons as part of the glioma microenvironment and describes neuronal signaling that drives glioma growth. The paper does not establish a dense network of adrenergic fibres, the listed stromal and immune-cell composition, or effects on non-brain cancers. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“intratumor microbes have been reported to have cancer-specific effects on (i) gastrointestinal and urinary tract mutagenesis via secreted genotoxins, most notably pks+ E. coli-derived colibactin and B. fragilis-derived toxin (22, 37, 38, 40, 41)”
§ The microbiome and human cancer > Overview of the cancer microbiome > Mechanisms and interactions between the gut and tumor microbiome
What the sources say
- Not checked yetcites [22] Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB, Paganelli FL, Geurts MH, Beumer J, Mizutani T, Miao Y, van der Linden R, van der Elst S, Genomics England Research Consortium, Garcia KC, Top J, Willems RJL, Giannakis M, Bonnet R, Quirke P, Meyerson M, Cuppen E, van Boxtel R, Clevers H, Mutational signature in colorectal cancer caused by genotoxic pks E. coli. Nature. 580, 269– 273 (2020). 32106218 PMC8142898 source
- Partly supportedcites [37] Wilson MR, Jiang Y, Villalta PW, Stornetta A, Boudreau PD, Carrá A, Brennan CA, Chun E, Ngo L, Samson LD, Engelward BP, Garrett WS, Balbo S, Balskus EP, The human gut bacterial genotoxin colibactin alkylates DNA. Science. 363 (2019), doi: 10.1126/science.aar7785. PMC6407708 30765538 sourceExperimental — accuracy not yet measured
The DNA-adduct experiments report colibactin-associated DNA damage in colonic epithelial cells and in mice colonized with pks+ E. coli. The Conclusions say resulting mutations may contribute to cancer, but do not establish cancer-specific mutagenesis. This paper does not support the sentence’s urinary-tract or B. fragilis-toxin components. (LLM, conf=0.87)
- Partly supportedcites [38] Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F, Sears CL, Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 359, 592– 597 (2018). 29420293 PMC5881113 sourceExperimental — accuracy not yet measured
The passage labeled Abstract (page not provided) identifies colibactin and B. fragilis toxin as secreted oncotoxins and reports increased colonic epithelial DNA damage and tumorigenesis when mice were cocolonized with the two bacteria. The paper concerns colonic mucosal biofilms in patients with familial adenomatous polyposis and colon-tumor models; it does not establish urinary-tract mutagenesis or effects of intratumor microbes across cancers. It attributes the observed DNA damage specifically to colibactin, rather than showing that B. fragilis toxin itself causes mutagenesis. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
59 more claims · 12 with their cited sources checked
Create a free account to see all 118 claims and to verify the 114 references still open.
- It may state two separate claims as one. 52
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The gut microbiome is increasingly recognized as a modifiable risk factor in multiple cancer types, including colorectal, gastric, and pancreatic cancers [12,41–43]”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recognition of the pivotal role of the microbiome in cancer initiation, progression, and treatment response has opened new avenues for therapeutic intervention [7–12]”
From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [12]
In the citing paper
“Parallel studies have demonstrated that the composition of the intestinal microbiota exhibits numerous disease-relevant changes in cancer patients.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The microbiome and human cancer > Overview of the cancer microbiome
“just 11 are labeled human carcinogens, or “oncomicrobes,” by the International Association for Cancer Registries (IACR) (36).”
§ The microbiome and human cancer > References
“36. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Biological agents. Volume 100 B. A review of human carcinogens.”
Citations
Cites
1 retracted
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2095-1 · Cited by 989
Self-citationRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Self-citationThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationRevised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425 · cited 1×
“1 to 1% are archaea and eukarya (including fungi) (27, 48).”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Moreover, observations in humans and mice of gut microbes that stratify therapy response, particularly immunotherapy (16, 17, 21, 26), have not uncommonly shown varying taxonomic differences that persist despite uniform bioinformatic reanalyses, although there is greater concordance when examining functional profiles…”
BackgroundSelf-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 1×
“Molecular mimicry between cancer and microbial antigens has also been hinted (82) and recently studied in depth (83).”
BackgroundCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“thatmediates Toll-like receptor 4 (TLR4)– and IL-12–dependent TH1 responses and therapeutic efficacy (70); (iii) inhibition of programmed cell death protein 1 and/or its ligand [PD-(L)1] leads to T cell priming against melanoma and is more effective when hosts harbor Bifidobacteria species in their microbiome (21, 71)…”
Background
Research works printed but not linked: 2
- W. Busch, Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl Klin Wochenschr 5, 137 (1868).
- T. J. Glover, The bacteriology of cancer. Canada Lancet Pract. 75, 92–111 (1930).
Cited by
Items 301–400 of 1,001
Live Biotherapeutic Products as Cancer Treatments
Brevi, A., & Zarrinpar, A. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2626 · Cited by 33
The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer
Kuštrimović, N. Z., Bilato, G., Mortara, L., & Baci, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031732 · Cited by 33
Assembly of functional microbial ecosystems: from molecular circuits to communities
Wu, S., Zhou, Y., Dai, L., Yang, A., & Qiao, J. (2024) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuae026 · Cited by 33
Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review
Petrelli, F., Ghidini, A., Dottorini, L., Ghidini, M., Zaniboni, A., & Tomasello, G. (2025) · Medicina · doi:10.3390/medicina61091595 · Cited by 33
Host–Microbiota Interactions in Liver Inflammation and Cancer
Giraud, J., & Saleh, M. (2021) · Cancers · doi:10.3390/cancers13174342 · Cited by 33
Chan, J. Y. K., Ng, C. W. K., Lan, L., Fung, S. Y. H., Li, J., Cai, L., Lei, P., Mou, Q., Meehan, K. L., Lau, E. H. L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.737843 · Cited by 33
Redrawing therapeutic boundaries: microbiota and cancer
Sholl, J., Sepich‐Poore, G. D., Knight, R. D., & Pradeu, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.008 · Cited by 33
Self-citationCell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity
Dean, J. W., & Zhou, L. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.01.008 · Cited by 33
Yang, S., Zhao, S., Ye, Y., Jia, L., & Lou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952546 · Cited by 35
Awareness of intratumoral bacteria and their potential application in cancer treatment
Liang, Y., Li, Q., Liu, Y., Guo, Y., & Li, Q. (2023) · Discover Oncology · doi:10.1007/s12672-023-00670-x · Cited by 33
Exploring food and medicine homology: potential implications for cancer treatment innovations
Li, M., Gu, A., Li, J., Tang, N., Matin, M., Yang, Y., Zengin, G., & Atanasov, A. G. (2025) · Acta Materia Medica · doi:10.15212/amm-2025-0003 · Cited by 32
Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments
Eiman, L., Moazzam, K., Anjum, S., Kausar, H., Sharif, E. A. M., & Ibrahim, W. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1575452 · Cited by 32
Human Microbiome and Its Medical Applications
Zhang, Y., Zhou, L., Xia, J., Dong, C., & Luo, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.703585 · Cited by 32
Brevi, A., Cogrossi, L. L., Lorenzoni, M., Mattorre, B., & Bellone, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845422 · Cited by 32
Saliva and Lung Microbiome Associations with Electronic Cigarette Use and Smoking
Ying, K. L., Brasky, T. M., Freudenheim, J. L., McElroy, J., Nickerson, Q. A., Song, M., Weng, D. Y., Wewers, M. D., Whiteman, N. B., Mathé, E. A., et al. (2022) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0601 · Cited by 32
Intratumoral microbiota: new frontiers in tumor immunity
Zhang, Z., Liao, Y., & Tang, D. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac063 · Cited by 32
Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris
Swallow, M. A., Fan, R., Cohen, J. M., & Bunick, C. G. (2022) · Antibiotics · doi:10.3390/antibiotics11081032 · Cited by 32
Sayin, S., Rosener, B., Li, C. G., Ho, B., Ponomarova, O., Ward, D. V., Walhout, A. J. M., & Mitchell, A. (2023) · eLife · doi:10.7554/elife.83140 · Cited by 32
Decoding the microbiome: advances in genetic manipulation for gut bacteria
Chen, Z., Jin, W., Hoover, A., Chao, Y., & Ma, Y. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.05.007 · Cited by 32
Lou, J., Cui, S., Li, J., Jin, G., Fan, Y., & Huang, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1279680 · Cited by 32
Untangling the web of intratumor microbiota in lung cancer
Liu, W. L., Xu, J., Pi, Z., Chen, Y., Jiang, G., Wan, Y., & Mao, W. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189025 · Cited by 31
Liu, Y., Kim, E. S., & Guo, H. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29485 · Cited by 31
Yin, T., Zhang, X., Xiong, Y., Li, B., Guo, D. M., Sha, Z., Lin, X., & Wu, H. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127871 · Cited by 31
Exploiting the obesity-associated immune microenvironment for cancer therapeutics
Desharnais, L., Walsh, L. A., & Quail, D. F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107923 · Cited by 31
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 31
microbioTA: an atlas of the microbiome in multiple disease tissues of Homo sapiens and Mus musculus
Wang, P., Zhang, S., He, G., Du, M., Qi, C., Liu, R., Zhang, S., Cheng, L., Shi, L., & Zhang, X. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac851 · Cited by 31
Al‐Manei, K., Ghorbani, M., Naud, S., Al‐Manei, K. K., Sobkowiak, M. J., Lund, B. K., Hazırolan, G., Chen, M., & Özenci, V. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02487-22 · Cited by 31
Bladder cancer-associated microbiota: Recent advances and future perspectives
Zhang, W., Yang, F., Mao, S., Wang, R., Chen, H., Ran, Y., Liu, S., Wu, P., Yan, Y., Li, W., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13012 · Cited by 31
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma
Tripodi, L., Feola, S., Granata, I., Whalley, T., Passariello, M., Capasso, C., Coluccino, L., Vitale, M., Scalia, G., Gentile, L., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107668 · Cited by 31
Flore, G., Deledda, A., Lombardo, M., Armani, A., & Velluzzi, F. (2023) · Antioxidants · doi:10.3390/antiox12101845 · Cited by 31
Liu, F., Guo, C., Li, X., Li, Y., Xu, S., James, T. D., & Wang, L. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102116 · Cited by 31
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives
Uher, O., Vanova, K. H., Taïeb, D., Calsina, B., Robledo, M., Clifton-Bligh, R. J., & Pacák, K. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae005 · Cited by 31
Yue, B., Gao, Y., Hu, Y., Zhan, M., Wu, Y., & Lu, L. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1731 · Cited by 31
Tumor-resident microbes: the new kids on the microenvironment block
Li, L., Chandra, V., & McAllister, F. (2024) · Trends in Cancer · doi:10.1016/j.trecan.2023.12.002 · Cited by 30
“Microbes play a critical role influencing the pathogenesis of several diseases, and their role in cancer has been recognized in recent years [8,9].”
BackgroundThe Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression
Souza, V. G. P., Forder, A., Pewarchuk, M. E., Telkar, N., de Araújo, R. P., Stewart, G. L., Vieira, J., Reis, P. P., & Lam, W. L. (2023) · Cells · doi:10.3390/cells12242801 · Cited by 31
Intratumoral bacteria generate a new class of therapeutically relevant tumor antigens in melanoma
Sepich‐Poore, G. D., Carter, H. K., & Knight, R. D. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.008 · Cited by 30
Self-citationLocal Breast Microbiota: A “New” Player on the Block
Vitorino, M. M., Costa, D. A., Vicente, R. S., Caleça, T., & Santos, C. (2022) · Cancers · doi:10.3390/cancers14153811 · Cited by 30
The Species of Gut Bacteria Associated with Antitumor Immunity in Cancer Therapy
Qi, X., Liu, Y., Hussein, S., Choi, G., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2022) · Cells · doi:10.3390/cells11223684 · Cited by 30
In vitro and ex vivo modeling of enteric bacterial infections
Taebnia, N., Römling, U., & Lauschke, V. M. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2158034 · Cited by 30
Perry, L. M., Cruz, S. M., Kleber, K. T., Judge, S. J., Darrow, M. A., Jones, L. B., Basmaci, U. N., Joshi, N., Settles, M. L., Durbin-Johnson, B. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004285 · Cited by 30
Advances in regulation and function of stearoyl-CoA desaturase 1 in cancer, from bench to bed
Guo, Z., Huo, X., Li, X., Jiang, C., & Xue, L. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2352-9 · Cited by 30
Ni, J., Ding, C., Zhang, J., Fang, X.-M., & Xiao, H. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.134984 · Cited by 30
Qin, W., Wang, S., Min, Y., Liu, X., Fang, J., Lang, J., & Chen, M. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03599-1 · Cited by 30
Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 29
Gao, J., Tang, L., Fu, C., Cao, Y., Liu, H., Yin, Y., Li, Z., Zhu, Y., Shu, W., Zhang, Y., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c00298 · Cited by 29
Yu, J., Liang, Y., Zhang, Q., Ding, H., Xie, M., Zhang, J., Hu, W., Xu, S., Xiao, Y., Xu, S., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.003 · Cited by 29
Gaskarth, D., Fan, S., Highton, A. J., & Kemp, R. A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1577906 · Cited by 29
Divergent tumor immunity determined by bacteria-cancer cell engagement
Yao, B., Liu, X.-M., Ruan, K., Fang, X., Jiang, C., Bian, W., Guo, Y., Zhu, X., Shang, Z., Hu, T., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.044 · Cited by 29
The intratumoural microbiota in cancer: new insights from inside
An, Y., Zhang, W., Liu, T., Wang, B., & Cao, H. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188626 · Cited by 29
Feng, P., Li, Z., Li, Y., Zhang, Y., & Miao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.799509 · Cited by 29
Qiao, H., Li, H., Wen, X.-H., Tan, X.-R., Yang, C., & Liu, N. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01068-22 · Cited by 29
Boytar, A. N., Nitert, M. D., Morrison, M., Skinner, T. L., & Jenkins, D. G. (2022) · The Journal of Physiology · doi:10.1113/jp283702 · Cited by 29
Li, T., Han, L., Ma, S., Lin, W., Ba, X. W., Yan, J., Huang, Y., Tu, S., & Qin, K. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1140325 · Cited by 29
Microbiota and Thyroid Disease: An Updated Systematic Review
Stramazzo, I., Capriello, S., Filardo, S., Centanni, M., & Virili, C. (2023) · Advances in experimental medicine and biology · doi:10.1007/5584_2023_770 · Cited by 29
Intratumoural microbiota: from theory to clinical application
Ji, H., Jiang, Z., Wei, C., Ma, Y., Zhao, J., Wang, F., Zhao, B., Wang, D., & Tang, D. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01134-z · Cited by 29
Guan, S.-W., Lin, Q., Wu, X., & Yu, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04411-0 · Cited by 29
The role of the gut microbiome in gastrointestinal cancers
Mishra, Y., Ranjan, A., Mishra, V. K., Chattaraj, A., Aljabali, A. A. A., El‐Tanani, M., Hromić‐Jahjefendić, A., Uversky, V. N., & Tambuwala, M. M. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.111013 · Cited by 29
The bacterial metabolite, lithocholic acid, has antineoplastic effects in pancreatic adenocarcinoma
Schwarcz, S., Kovács, P., Nyerges, P., Ujlaki, G., Sipos, A., Uray, K., Bai, P., & Mikó, E. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02023-1 · Cited by 29
Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration
Raoul, J., & Hansten, P. D. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102794 · Cited by 28
Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies
Basu, R., Boguszewski, C. L., & Kopchick, J. J. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae030 · Cited by 28
Liu, Z., Jiang, Y., Fan, Q., Li, S., & Wang, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s540163 · Cited by 28
Exploiting metabolic vulnerabilities in cancer: From mechanisms to therapeutic opportunities
Xue, Z.-R., Xin, Y.-Y., & Jin, W. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218067 · Cited by 28
Taxonomic and Functional Dysregulation in Salivary Microbiomes During Oral Carcinogenesis
Chen, J.-W., Wu, J., Chiang, W.-F., Chen, Y., Wu, W.-S., & Wu, L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.663068 · Cited by 28
The microbiome, gastrointestinal cancer, and immunotherapy
Newsome, R. C., Yang, Y., & Jobin, C. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15742 · Cited by 28
The bacteria inside human cancer cells: Mainly as cancer promoters
Zhu, W., Wang, J., Liu, Z., & Wei, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.897330 · Cited by 28
Frąk, M., Grenda, A., Krawczyk, P. A., Milanowski, J., & Kalinka‐Warzocha, E. (2022) · Cancers · doi:10.3390/cancers14225577 · Cited by 28
Immuno-oncology-microbiome axis of gastrointestinal malignancy
Lin, Q., Guan, S.-W., & Yu, H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.757 · Cited by 28
Chen, Z., Liu, Y., Yu, Y., Yang, S., Feng, J. Q., Zhu, Y., Huang, W., Qin, B. Y., Guan, X., He, Z., et al. (2023) · Advanced Materials · doi:10.1002/adma.202306488 · Cited by 28
Shiver, A. L., Sun, J., Culver, R., Violette, A., Wynter, C., Nieckarz, M., Mattiello, S. P., Sekhon, P. K., Bottacini, F., Friess, L., et al. (2025) · Cell · doi:10.1016/j.cell.2025.02.010 · Cited by 27
Fusobacterium nucleatum carcinogenesis and drug delivery interventions
Chen, Z., & Huang, L. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115319 · Cited by 27
Kundu, I., Varshney, S., Karnati, S., & Naidu, S. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102286 · Cited by 27
A comprehensive review on utilizing CRISPR/Cas system for microbiome modification
Abavisani, M., Faraji, N., Faraji, S., Ebadpour, N., Kesharwani, P., & Sahebkar, A. (2024) · Biochemical Engineering Journal · doi:10.1016/j.bej.2024.109443 · Cited by 27
Li, J., Zhou, W., Wang, H., Huang, M., & Deng, H. (2024) · MedComm · doi:10.1002/mco2.70019 · Cited by 27
Advancing cancer research via comparative oncology
Vincze, O., Spada, B., Bilder, D. H., Cagan, A., DeGregori, J. V., Gorbunova, V. A., Maley, C. C., Schiffman, J. D., Seluanov, A., Giraudeau, M., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00841-8 · Cited by 27
Li, J., Zhang, C., Huang, X., Sun, H., Yang, L., Liu, H., Zhang, L., Wu, N., Xie, Y., Qi, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.02.001 · Cited by 27
Trifanescu, O. G., Trifanescu, R. A., Mitrica, R. I., Bran, D. M., Serbanescu, L. G., Valcauan, L., Marinescu, Ș. A., Gales, L. N., Tănase, B. C., & Anghel, R. M. (2023) · Diagnostics · doi:10.3390/diagnostics13050877 · Cited by 28
Microbiomic profiles of bile in patients with benign and malignant pancreaticobiliary disease
Poudel, S. K., Padmanabhan, R., Dave, H. M., Guinta, K. M., Stevens, T., Sanaka, M. R., Chahal, P., Sohal, D. P. S., Khorana, A. A., & Eng, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283021 · Cited by 27
Lederer, A., Rasel, H., Kohnert, E., Kreutz, C., Huber, R., Badr, M. T., Dellweg, P. K. E., Bartsch, F., & Lang, H. (2023) · Microorganisms · doi:10.3390/microorganisms11092363 · Cited by 27
Potential Role of the Intratumoral Microbiota in Prognosis of Head and Neck Cancer
Hamada, M., Inaba, H., Nishiyama, K., Yoshida, S., Yura, Y., Matsumoto‐Nakano, M., & Uzawa, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015456 · Cited by 27
Cancer and the Microbiome of the Human Body
Herrera‐Quintana, L., Vázquez‐Lorente, H., López-Garzón, M., Cortés‐Martín, A., & Plaza‐Díaz, J. (2024) · Nutrients · doi:10.3390/nu16162790 · Cited by 27
Emerging roles of intratumor microbiota in cancer: tumorigenesis and management strategies
Shi, Z., Li, Z., & Zhang, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05640-7 · Cited by 27
Microbiota in tumors: new factor influencing cancer development
Jiang, H., Li, L., Bao, Y., Cao, X., & Ma, L. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00833-0 · Cited by 27
Regulatory Considerations for Microbiome-Based Therapeutics
Waheed, R., Farooq, A. Z., & Asma, L. (2024) · Springer eBooks · doi:10.1007/978-981-97-3790-1_21 · Cited by 26
Zhang, B., Sahardi, N. F. N. M., Di, W. J., Long, X., & Shafiee, M. N. (2025) · Cancers · doi:10.3390/cancers17061044 · Cited by 26
The Hallmarks of Cancer as Eco-Evolutionary Processes
Bhattacharya, R., Avdieiev, S. S., Bukkuri, A., Whelan, C. J., Gatenby, R. A., Tsai, K. Y., & Brown, J. S. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0861 · Cited by 26
Iwata, S., Nishiyama, T., Sakari, M., Doi, Y., Takaya, N., Ogitani, Y., Nagano, H., Fukuchi, K., & Miyako, E. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01459-9 · Cited by 26
Wang, Y., Xiao, S., Yu, W., Han, B. R., & Guo, G. F. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01766-3 · Cited by 26
The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments
Son, Y. M., & Kim, J. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2208.08002 · Cited by 26
Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma
Yang, J.-W., Wan, S., Li, K., Chen, S., & Yang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188520 · Cited by 26
Arbel, M., Menuhin-Gruman, I., Naki, D., Bergman, S., & Tuller, T. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.06.008 · Cited by 26
Fungi and tumors: The role of fungi in tumorigenesis (Review)
Cheng, W., Li, F., Gao, Y., & Yang, R. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5640 · Cited by 26
Unveiling intratumoral microbiota: An emerging force for colorectal cancer diagnosis and therapy
Zhang, J., Wang, P., Wang, J., Wei, X., & Wang, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107185 · Cited by 26
Fan, H., Wang, Y., Han, M., Wang, L., Li, X., Kuang, X., Du, J., & Peng, F. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1344284 · Cited by 26
Xin, Y., Peng, G., Song, W., Zhou, X., Huang, X., & Cao, X. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1366131 · Cited by 25
The lung, the niche, and the microbe: Exploring the lung microbiome in cancer and immunity
Huynh, M., Crane, M. J., & Jamieson, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1094110 · Cited by 25
Vaginal and tumor microbiomes in gynecological cancer (Review)
Han, M., Wang, N., Han, W., Ban, M., Sun, T., & Xu, J. (2023) · Oncology Letters · doi:10.3892/ol.2023.13739 · Cited by 27
Metagenomics reveals novel microbial signatures of farm exposures in house dust
Wang, Z., Dalton, K. R., Lee, M. K., Parks, C. G., Freeman, L. E. B., Zhu, Q., González, A., Knight, R. D., Zhao, S., Motsinger‐Reif, A. A., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1202194 · Cited by 25
Self-citationSong, H., Guo, R. H., Sun, X., Kou, Y., Ma, X., Chen, Y., Song, L., Yuan, C., & Wu, Y. (2023) · Food & Function · doi:10.1039/d3fo02688d · Cited by 25
The microbiota and renal cell carcinoma
Wu, K., Li, Y., Ma, K., Zhao, W., Yao, Z., Zheng, Z., Sun, F., Mu, X., Liu, Z., & Zheng, J. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00876-9 · Cited by 25
Gastric Cancer: The Microbiome Beyond Helicobacter pylori
Mendes-Rocha, M., Pereira‐Marques, J., Ferreira, R. M., & Figueiredo, C. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-47331-9_6 · Cited by 25
Metadata
- Authors
- Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R.
- Affiliations
- Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA.
- Université Paris-Sud (FR)
- Weizmann Institute of Science (IL)
- University of California San Diego (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Knight, Rob
- ORCID
- Venue
- Science
- Published
- 2021-03-26
- Volume
- 371
- Issue
- 6536
- Pages
- 91-97
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8767999
- OpenAlex
- W3138215020
- Cited by
- 1,332
- References
- 176
- Citations by year
- 2026: 231 · 2025: 310 · 2024: 294 · 2023: 274 · 2022: 161 · 2021: 62
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-09-26)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (F30 CA243480, R01CA255206)
- RHU Torino Lumière (ANR-16-RHUS-0008)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- microbiome, cancer, gut microbiota, antitumor immunity, microbial metabolites, Toll-like receptors, immune checkpoint inhibitors, intratumoral bacteria, bacteriophages, gastrointestinal cancer, cancer immunotherapy, microbiota modulation, engineered bacteria, Rous sarcoma virus, viral oncogenesis, molecular mimicry
- MeSH terms
- Gastrointestinal Microbiome, Host Microbial Interactions, Anti-Bacterial Agents, Antineoplastic Agents, Bacteria, Genetic Engineering, Humans, Immunotherapy, Lymphoid Tissue, Neoplasms, Virus Physiological Phenomena, Bacterial Physiological Phenomena, Oncolytic Virotherapy, Adaptive Immunity, Immunomodulation, Tumor Microenvironment, Carcinogenesis, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.